Apellis Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (12 Ratings)
Portfolio Pulse from Benzinga Insights
Apellis Pharmaceuticals (NASDAQ:APLS) has received 12 analyst ratings in the last three months, with a mix of bullish and bearish sentiments. The average 12-month price target is $67.67, down from the previous $69.40. Analysts from firms like Goldman Sachs, Citigroup, and others have adjusted their price targets and ratings, reflecting their latest views on the company's performance. Apellis Pharmaceuticals is a clinical-stage biopharmaceutical company with a focus on the complement system. Despite a significant revenue growth rate of 400.54% as of September 30, 2023, the company's net margin and ROE are below industry averages, and it has a prudent debt-to-equity ratio of 0.47.
January 09, 2024 | 3:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Apellis Pharmaceuticals has a diverse range of analyst ratings with an average 12-month price target of $67.67. The company has shown impressive revenue growth but struggles with profitability and efficiency.
The mixed analyst ratings and the recent decline in the average price target suggest uncertainty, which could lead to a neutral short-term impact on the stock price. The impressive revenue growth is a positive sign, but the below-average net margin and ROE may raise concerns about long-term profitability and efficiency, potentially offsetting the positive sentiment.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100